

## Is high COVID-19 vaccination reducing natural immunity?

Indrani Roy  
University College London (UCL)

[Indrani.roy@ucl.ac.uk](mailto:Indrani.roy@ucl.ac.uk); [Indrani\\_r@hotmail.com](mailto:Indrani_r@hotmail.com)

Lazarus Chapungu

Exxaro Chair in Climate and Sustainability Transitions, University of South Africa,  
Pretoria, South Africa. [Email: tchapul@unisa.ac.za](mailto:tchapul@unisa.ac.za); [lchapungu@gmail.com](mailto:lchapungu@gmail.com)

**Abstract.** This analysis, using published authentic data, will explore the existing/ guided strategy of the global mass vaccination program to combat the COVID-19 crisis. It mainly focused on countries that experienced unprecedented deaths in the later period and the period covered is till 21st March 2022. The peak of deaths in later months reached an all-time high since the beginning of the pandemic. Nine countries identified in that category are Singapore, South Korea, Australia, Hong Kong, Iceland, New Zealand, Denmark, Finland and Japan. Almost all of those countries had nominal cases and deaths prior to September 2021 (vaccine third dose was initiated). Interestingly, all those nine countries had very high vaccination rates and were among the topmost vaccinated countries during the covered period. Israel started mass vaccination first and initiated the fourth dose at the beginning of January 2022; soon afterward, not only cases but also, deaths reached an all-time high. Israel also introduced vaccine doses among children of various age groups first and was in fact, leading or guiding the vaccine roll-out strategy. Gibraltar on the other hand implemented the most successful mass vaccination programme, from the beginning. Gibraltar was the country that achieved the highest target for vaccination at the earliest. It attained and maintained 100% vaccination since May 2021, though cases of the latest peak in March 2022 reached an unprecedented high for the whole of the pandemic. All the data analysed here started from the beginning of the pandemic and was presented using government official COVID tool [Ourworldindata](https://ourworldindata.org/). Moreover, cases as well as deaths in later periods among vaccinated groups, were also compared with the unvaccinated ones, for the UK, based on the country's government report. That indicated an unusual surge of cases and deaths in later periods among vaccinated groups compared to the unvaccinated ones. Various observed facts, supported by well-known and established scientific theories, indicate that high vaccination may weaken natural immune response which needs urgent policy action.

**Key Words:** COVID-19, vaccine, mass vaccination, adverse effect, natural immunity

**Highlights:**

\*Nine countries identified where peak of deaths in later months reached all-time high

\*Period covered till 21 Mar '22 and all nine were among topmost vaccinated countries

\*Cases and deaths were nominal in those countries before the start of third dose

\*Observation shows unusual surge in cases/deaths among fully vaccinated groups

\*Scientific theories indicate high vaccination may weaken natural immune response

## 1. Introduction.

The pandemic of **CO**rona**VI**rus **D**isease **2019** (COVID-19) killed more than 6.09 million people globally till 21<sup>st</sup> March 2022 [1] and severely impacted the economy and mental health. The first patient reported to get admission in hospital at China was on 12 December 2019 [1a] and in the beginning of February, 2020 the pandemic began to spread all over the world [1]. Soon afterwards, major lockdowns were imposed across most of the globe, leading to further worsening of the situation. The responsible virus for the disease is Severe Acute Respiratory Syndrome CoronaVirus 2 (**SARS-CoV-2**) and detailed discussions on the nature of the disease and characteristics of the virus are nicely outlined in current research [2, 3]. Continuous emergence of various viral variants is a major threat to countermeasures of pandemics due to the antibody neutralization escape [3a] and enhanced transmission [3b, c, d]. This paper has compiled evidence from official and government records for several countries, that collectively suggest a new dimension to existing exit strategy and has policy implications.

To combat the COVID-19 crisis, various vaccination groups took leading initiatives with coordinated efforts. Till two years of the pandemic, vaccines were considered the only pathway to overcome the crisis [World Health Organisation (WHO)] and were heavily promoted. More than 65% of the world population already received at least one dose of the COVID-19 vaccine [1]. Various types of vaccines are in place and the technology and compositions are discussed in detail [4, CDC<sup>1</sup>]. At least 4 principally different covid-19 vaccines are in use: i) m-RNA Vaccines, ii) vector-borne vaccines, iii) inactivated viruses from China and India, and iv) viral surface proteins. Among these vaccines, Pfizer-BioNTech is most widely used in the US and Europe followed by Moderna [Fig. S1]. Both the vaccines use m-RNA technology. Various other vaccines are also available [Fig. S1]. Vector-borne vaccines are widely administered among which are Johnson & Johnson and AstraZeneca. Sputnik V is an Adenovirus viral vector vaccine, which is mainly used in Russia. Chinese companies Sinopharm and Sinovac use inactivated viruses. Indian company Bharat Biotech developed Covaxin using the similar technology to Sinovac. Whereas, Novavax is a protein-based vaccine.

Approval of the COVID-19 vaccine was unusually prompt though relating to COVID-19 vaccine trials, concerns were initially raised that studies seem designed to answer not the most clinically relevant questions and trials were not designed to say whether these vaccines can save lives [5]. Following speedy vaccine approval, another study discussed "Science by press release" is just one of many flaws in the way new treatments are evaluated, brought into stark relief by the pandemic' [6]. That quoted comment indicated that more coordination and coherence was indeed required for timely comparisons and evaluations between various treatments to combat crisis like COVID pandemic. Studies further evaluated exit strategy via vaccination and discussed some striking resemblance of Flu with COVID-19 and also discussed various direct and indirect effects of mass vaccination [7, 7a]. Regarding exit pathways via vaccination, scientists followed observation and were right to mention that rapid regulatory approval and roll-out of several vaccines though have ignited much optimism, but such optimism is unwarranted in the face of the occurrences of many new variants which are less sensitive to vaccine-induced antibodies [8]. Exit strategy other than vaccination is also suggested in earlier research [8a].

After the initiation of mass vaccination, many adverse effects from vaccines, even deaths were reported (CDC<sup>2</sup>); though medium and long-term effects are yet to be investigated properly. The percentage of reporting adverse reactions is much higher compared to other existing approved vaccines (CDC<sup>2</sup>). For a small country UK, more than one lakh of adverse reporting were made

---

CDC : Centers for Disease Control and Prevention

CDC<sup>1</sup>, <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html>

CDC<sup>2</sup>, <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html>.

between 09/12/20 and 06/04/22 only for mRNA Pfizer/BioNTech vaccine [UHSA<sup>3</sup>, total reactions: 4,85,939; total reports: 1,68,927; fatal outcomes: 746). The basis of various adverse reactions of COVID-19 vaccines from a biological science perspective was analysed thoroughly [9]. A recent review also nicely depicted the scientific basis of many adverse effects of the SARS-CoV-2 vaccines in an excellent way [10].

After the second dose, antibodies induced by the vaccines dissipate in as little as 3–10 weeks' time [11], and hence people are advised to get booster shots at regular intervals (CDC<sup>4</sup>). With 2 doses of Moderna or Pfizer vaccine, effectiveness was found to drop from around 65 to 70% down to around 15% by 25 weeks after the second dose as discussed in UK Health Security Agency (UHSA) government report [UHSA<sup>5</sup>, page 4]. Whereas, two to 4 weeks after a booster dose, effectiveness ranges from around 60 to 75%, dropping to 25 to 40% after 15 weeks. These findings raise questions about vaccinating the whole global population every few months interval and prompt the need of analysing thorough risk-benefit analyses with a critical viewpoint. Despite knowing the effects of vaccination fade in a few months' time and the Death rate due to COVID-19 among children is practically negligible, child vaccinations have been initiated. Apart from other usual adverse effects of COVID-19 vaccine, children disproportionately reported (based on gender, age and dose) heart-related inflammation (known as Myocarditis/ Pericarditis). Disproportionate and much higher percentages were reported for males than females and also for younger age groups below 18. Effects were noted much higher after the 2<sup>nd</sup> dose. [CDC<sup>6</sup>: CDC's COVID-19 Vaccine Safety Technical Work Group]. A cohort study considering students from two schools in Thailand, aged 13–18 years explored Cardiovascular manifestation in adolescents after BNT162b2 mRNA COVID-19 vaccination [11a]. Cardiovascular manifestations were found in 29.24% of patients, ranging from palpitation or tachycardia to myopericarditis [11a] though long-term effect is not possible to identify yet.

The current study mainly focused on the later months of the pandemic from the study period (till 21<sup>st</sup> March 2022). Since the initiation of the third dose many topmost vaccinated countries experienced an unusual surge in deaths; whereas, deaths and cases for those countries were nominal prior to that. Countries that took the most coercive measures including vaccine mandates, stringent vaccine rules and restrictions are among the worst hit in the later period in terms of deaths (and of course cases too) e.g., Canada, New Zealand and Australia. New Zealand and Australia were least affected due to COVID-19 in earlier periods though transmission and deaths became unprecedented in later times. Such observation prompted the need to explore the situation further and examine critically the overall planned vaccine strategy. The current analyses critically evaluate those situations and have urgent policy implications.

In Israel, 80% of the eligible population got two doses of vaccine alongside the booster dose. Those include 90% of people over the age of 60 years. Israel started vaccinating 5–11-year

---

UHSA<sup>3</sup>,

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1069177/COVID-19\\_Pfizer-BioNTech\\_Vaccine\\_Analysis\\_Print\\_DLP\\_6.04.2022.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1069177/COVID-19_Pfizer-BioNTech_Vaccine_Analysis_Print_DLP_6.04.2022.pdf)

CDC<sup>4</sup>, <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html> accessed 25/4/22

UHSA<sup>5</sup>:

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1066759/Vaccine-surveillance-report-week-13.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1066759/Vaccine-surveillance-report-week-13.pdf)

CDC<sup>6</sup>, <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/03-COVID-Shimabukuro-508.pdf>, accessed 15/04/21

children in November 2021 and initiated the 4<sup>th</sup> dose in January 2022 [12]. Hence Israel can be looked upon for monitoring purposes in terms of the performance of vaccines among the mass community. It can indicate an advanced overview of how mass vaccination fares and how immunity wanes over time. Those observations can play a crucial role to set and reform vaccine rollout strategies in other countries. The focus will also be on another country Gibraltar which can be set as an example of the vaccine success story. It maintained a 100 percent vaccination rate since May 2021 [1].

This analysis, using already published authentic data, will explore the existing/guided strategy of global mass vaccination programme to combat the COVID-19 crisis. It discussed whether the COVID vaccines is increasing risk to infection and even death, after the initial boost in antibody levels has fallen off. The period covered is till 21<sup>st</sup> March 2022. It will examine critically some risk-benefit issues among few countries in chosen categories pointwise and can give direction of policy evaluation globally.

## **2. Methodology:**

The research design of the study can be described as follows. Some countries which showed success in managing COVID-19 during the earlier period of the pandemic are the main focus here. Those countries gathered enough attention with very low case and death rates, while most countries struggled hard with very high fatality rates around the same period. Surprisingly, when those countries with very low cases and deaths suddenly showed a surge since September 2021, the period when the third dose started in most countries, it indicated that those particular countries need to be explored further what other situations changed there, that caused such an adverse outcome. This analysis focused the period from the beginning of the pandemic (start of 2020) till the 21<sup>st</sup> of March 2022 and covered more than two years period. Countries are randomly placed all over the globe. The only criteria for choosing the countries are that all showed an unusual surge in cases as well as deaths in the later six months period though had nominal fatalities in the earlier period of the pandemic.

Questions could be there for reasons of low fatality rates in those countries during the earlier period. Strong innate natural immunity of people in some countries could be one reason. Clinical trial experiments indicated some foods and vitamins can strengthen natural immunity. In some countries specific food habits may have played roles for low transmissions and deaths in the earlier periods (e.g., South Korea, Japan, Hong Kong); whereas low population density could also have an influence on some countries (Australia, Iceland, Finland).

In regard to choosing the target population in this analysis, no specific age ranges or sex were focused on, nor any particular demography, ethnicity or food habits were considered. Countries discussed here were scattered all around the globe- some were tropical countries and some were from polar regions; some were from the northern hemisphere and some from the southern hemisphere; neither particular season received attention. Some countries have very high population density, while some have very low. The main focus is the comparison of cases and deaths between a later period (around six months or less) to that from the earlier period of the pandemic and attention is on vaccination status in those countries. To eliminate effects of population density and compare different countries together, parameters (e.g., cases, deaths and vaccine doses) are presented in terms of the number of overall populations of each country.

The hypothesis we are going to test is that if we eliminate all other confounding factors, whether it is possible to identify any reasons that can cause such unusual rates of death and case to some specific countries in the later period, those performed really well in the earlier period. In this study, to test that hypothesis, some countries were chosen based on the following three categories:

- i) *Countries with unusual deaths in the later few months:* For some countries deaths in later months reached an all-time high since the beginning of the pandemic. The latest peak of deaths, after the start of the third dose, became the highest peak in respective countries: Nine countries were identified viz. **Singapore, South Korea, Australia, Hong Kong, Iceland, New Zealand, Denmark, Finland and Japan.** [1]. Those countries are shown in Fig.1A, which are not localised to closer latitude and longitude bands. Those are not neighbouring countries but located all around the globe. Moreover, some countries are smaller in size and some are larger; while some countries have higher population density and others have lower. The effect of seasonal climatic conditions is not dominating results as some countries are located in the northern hemisphere and some are in the southern hemisphere.
- ii) *Country leading/ guiding the vaccine roll-out strategy:* The country **Israel** started the mass vaccination first and pioneering in terms of initiating new doses among the population and starting vaccination among the new age groups of children. Israel is leading the direction of vaccine roll-out strategy and is much ahead, in time than other countries [1, 12].
- iii) *Highest vaccination:* **Gibraltar** is the country that achieved the highest target of vaccination first. It attained and maintained 100% vaccination since May 2021 [1].

### 2.1. Data Analyses.

The study carried out various time-series analyses and applied simple statistical concepts, while critical approaches were adopted to interpret statistical results. The period covered is till 21<sup>st</sup> March 2022 and open data sources are used [1]. The main data used are COVID-19 deaths, cases and vaccine doses in specified countries. Data are generated by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) [1].

For time series analyses, data for daily deaths, cases and vaccine doses, all for 7-day averages, in terms of the overall population are used. Cumulative measures of those parameters have also been analysed in some cases to grasp certain variations better. For vaccine doses, the numbers of daily COVID-19 doses administered are considered, where all doses are counted individually (including boosters). Horizontal bar charts are used to depict shares of people vaccinated against COVID-19 with various doses. Analyses were shown for a few countries with the breakdown of people who completed the initial protocol of vaccine dose and those only partially vaccinated. A further breakdown, in terms of initial doses and boosters per 100 people for some countries is also presented. The total numbers of doses administered are broken down by whether they are part of the initial protocol or booster doses, divided by the total population of the country [1]. Such representation, in terms of population, makes comparison among various countries easier. COVID-19 vaccine doses administered based on the manufacturer are also shown for European Union and the US. There, all doses, including boosters, were counted individually.

Cases, as well as deaths in later periods among vaccinated groups, were also compared with the unvaccinated ones, for the UK, based on the country's government report, the UK government weekly report [UK Health Security Agency (UHSA) and Public Health Scotland (PHS)]. Finally, all observed and analysed facts discussed in this study were linked with well-known, established scientific theories to provide directions to urgent policy action.

### 3. Results and Discussion:

Data were analysed and presented for some specified countries as follows:

-----  
**Note:** In the whole analysis, alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries. [Source: Our World in Data (1)]

### 3.1. Countries with unprecedented deaths in the later period and vaccination status

Here the main focus is on deaths in the later period. As most countries started the third dose around September 2021, the period after 3<sup>rd</sup> dose is considered the later period which is the focus here. I chose only those countries that experienced unprecedented deaths in that period (and of course cases too) and those countries are Singapore, South Korea, Australia, Hong Kong, Iceland, New Zealand, Denmark, Finland and Japan. All those nine countries are seen as topmost vaccinated countries in that plot (Fig. 1B). For easy comparison, a few other likely vulnerable countries are also included at the bottom of that plot; among those are highly populated countries e.g., India, Bangladesh alongside countries that had very high overall Death rates per million for the whole of the pandemic e.g., US, UK, Europe etc. For all those top nine countries, not only cases but deaths also reached an all-time high in the latter period (Fig. 2). Interestingly, those are the most vaccinated countries on that list. Countries at the bottom of that list, although they administered much less vaccination, performed relatively well in recent surges compared to those nine countries. For the US and European countries, cases this winter peaked all-time high though deaths were lower than the highest peak in their respective countries. Figures of cases and deaths for the US, Europe, UK and India are also shown (Fig. S2). For India, a heavily populated country, the latest peak of cases was even lower than the previous peak and the latest peak of deaths was the weakest of all peaks (Fig. S2, d). Interestingly, in terms of vaccination, India is placed at the bottom of the list (Fig. 1B). Another highly populated country Bangladesh also fared well like India during the latest surge [1].

Countries like Canada, New Zealand and Australia which took the most coercive measures including vaccine mandates, stringent vaccine rules and restrictions are among the worst hit in the recent period in terms of deaths. Those countries not only administered high vaccination but with less population density, also experiencing an increased rate of transmission following vaccination. On the other hand, based on high population density Singapore and South Korea had disadvantages. Surprisingly, deaths and cases were nominal in those countries in the first one and half years of the pandemic. Whether it was guided by strong natural immunity due to high population density or not, needs to be investigated further. However, deaths/cases skyrocketed in the later months. Singapore and South Korea are not only the topmost vaccinated countries in that list (Fig. 1B), but also administered one of the highest percentages of booster doses (steepest rise compared to Europe, US and India as shown in Fig. S3). Cases and deaths in the later periods were unprecedented and all time high (Fig. 2).

It is a similar story for Japan and Hong Kong - apart from high population density and very high vaccination rates, both had high booster intakes (Fig. S3). Moreover, there was a sudden very steep increase in vaccine uptake in Hong Kong and Japan starting in the beginning of January 2022; while, interestingly, during the same time period, most other countries saw a decrease in vaccine doses (Fig. S4). Among all those nine countries, Hong Kong performed the worst, as daily deaths (7-day average) even exceeded 30 per million (Fig 2, shown by the Y axis). For Hong Kong, the latest rise in vaccine doses was not only at the steepest rate since the start of mass vaccination, but the peak of doses also exceeded an all-time high (Fig. S4). It is noteworthy to mention that after the initiation of the initial mass vaccine programme, or a sudden rise in doses, almost all countries experienced a rapid surge in transmission and most countries had to impose strict lockdown measures [BMJ<sup>7</sup>, 7].

**Such observation with all those 9 countries that experienced unusual surges in deaths (though almost all had nominal cases and deaths in the earlier period) raises an obvious question of whether vaccination might be causing impairments in natural immunity.**


***Additional Comments:***

a) *Reverse may not be true for all very highly vaccinated countries:* The observation for very highly vaccinated countries can still be different as other confounding factors can also influence results. There are of course various other factors involved e.g., increase/decrease rate of vaccination (hence I am focusing only upto 21<sup>st</sup> March, 2022), number of third doses, environmental factors, dominated by people of old age etc. Thus, the reverse may not be always true for all topmost vaccinated countries.


b) *Observation can be altered if the end date of this analysis is extended:* There are also possibilities that the observation noted here may be altered by changing vaccine doses in some countries after 21<sup>st</sup> March, 2022. After that particular date if vaccine doses in some particular countries suddenly are varied or new vaccine doses are initiated or new age groups of children are included, all those can heavily impact observed/ discussed results too.

However, the main point here is that inspite of all those influences and confounding factors, observation presented here considering the period up to 21<sup>st</sup> March, 2022 **can not be disregarded or overlooked by any means.** It has important policy implications.

A)




B)




**Fig. 1:** A) Map of the globe marking nine countries that experienced unprecedented deaths in the later period (period from the beginning of the pandemic till 21<sup>st</sup> March 2022). Countries in that

category are: a) Singapore, b) South Korea, c) Australia, d) Hong Kong, e) Iceland, f) New Zealand, g) Denmark, h) Finland and i) Japan. Two very small countries Hong Kong and Singapore are difficult to show by colour coding and hence marked directly, though rest seven countries are marked with colours. B) Shares of people vaccinated against COVID-19 are shown for a few countries (till 21<sup>st</sup> March 2022). The vaccination status of those nine countries is placed at the top.


a)



b)




c)



d)




e)




f)




g)



h)



i)



**Fig. 2:** Daily new confirmed COVID-19 cases and deaths per million people, 7-day rolling average, for countries those experienced unprecedented deaths in the later period. Countries in that category are: a) Singapore, b) South Korea, c) Australia, d) Hong Kong, e) Iceland, f) New Zealand, g) Denmark, h) Finland and i) Japan. The period of analysis is till 21<sup>st</sup> March 2022 and vaccine status of those countries of are also shown in Fig 1B. [ Source: Our World in Data (1)]

### 3.2. Latest performance of the country that leads/ guides vaccine roll-out strategy: Israel

In Israel, 90% of people over the age of 60 years got two doses of vaccine alongside the booster dose. Israel is the country that first started vaccinating 5–11 years age group children and also first initiated the 4<sup>th</sup> dose in January 2022 [12]. Israel can be looked upon for monitoring purposes by other countries, in terms of the performance of vaccines among the mass community.

Israel also started 3<sup>rd</sup> dose earlier (in July) than other countries (most countries started from September 2021) and from 1<sup>st</sup> August Israel suddenly increased the third dose [1]. A new peak in cases, as well as deaths, appeared [Fig. 3a]. Israel is the first country that started the fourth dose at an earliest, which is at the beginning of January [12] and interestingly, the timing coincided with the start of the highest peak of waves in cases and deaths. Both the latest peak in cases and deaths appeared to be all-time highs over the whole of the pandemic [Fig. 3a].

Before starting the 4<sup>th</sup> Dose in any country, careful analyses of the situation in Israel can offer a useful perspective. Observation from Israel can play a crucial role to reform and implement vaccine rollout strategies in other countries too.


### 3.3. Highest vaccinated country: Gibraltar

Gibraltar is the country that maintained a 100 percent vaccination rate for a long time. It attained and maintained 100% vaccination since May 2021. However, cases this winter (2021-'22) became an all-time high (Fig. 3b and c). The recent peak in cases is not only the highest peak of


all, but in terms of the width of waves too it exceeded all previous records (Fig. 3b). Gibraltar shows vaccination status even exceeding 100% (Fig. 3c) as they vaccinated all non-residents too and do not allow anyone to enter the country without full vaccination. Fig. S5 further shows Gibraltar is highly ranked not only in terms of cumulative vaccine doses but also in terms of cumulative cases too.

All the observed data and analyses point towards high vaccination and losing natural immunity. That supports the latest unprecedented surges in Covid-19 deaths in Singapore, South Korea, Australia, Hong Kong, Iceland, New Zealand, Denmark, Finland, Japan and Israel.

a)



b)



c)



**Fig. 3.** Daily new confirmed COVID-19 cases and deaths, per million people (7-day rolling average) for **Israel** (a). The same for only cases for **Gibraltar** (b). Share of people in **Gibraltar**

who completed all doses prescribed by the initial vaccination protocol (c). The period covered is till 21<sup>st</sup> March 2022 [ Source: Our World in Data (1)]

### 3.4. Unusual surge in cases/deaths among vaccinated groups compared to unvaccinated.

The UK government weekly report [UK Health Security Agency (UHSA)] included vaccinated vs. unvaccinated statistics that indicated the absolute number of deaths among vaccinated was increasing at a much higher rate than the unvaccinated group. Record of deaths within 28 days or 60 days of positive COVID-19 test by date of Death suggested approximately for every 6 deaths from COVID-19 of above 50 years age group (period covered between week 43 and 46, 2021, UHSA<sup>8</sup>), only 1 was unvaccinated and the rest received at least one dose, Table S1). In terms of the percentage of total deaths during those weeks, approximately 17 % were unvaccinated, while 80 % were fully vaccinated [Table S1, UHSA<sup>8</sup>]. Whereas, in the later period, for weeks 9-12, 2022, deaths within 28 days (60 days) of positive COVID-19 suggest approximately 9.5% (7.3%) were unvaccinated, and even 73.4% (76.1%) were triple jabbed (Table S1, UHSA<sup>5</sup>). As time passed from 28 days to 60 days, the percentage of deaths among unvaccinated decreased (by more than 2%), while deaths among triple jabbed increased from 73.4% to 76.1% (Table S1). People aged 50 years and above are presented here, as they are the most vulnerable categories in terms of deaths.

When the focus is on cases, it is seen percentages of unvaccinated populations are also getting less infected compared to the fully vaccinated proportion (Table 1). The same UHSA reports for week 47, 2021 (UHSA<sup>8</sup>) and week 13, 2022 (UHSA<sup>5</sup>) show cases (in terms of percentage) among fully vaccinated people (even with third doses) are also rising at a much higher rate compared to the unvaccinated groups and is true for various age groups too (Table 1). Case numbers for individuals testing positive for the virus are seen persistently lower amongst the unvaccinated, while Case numbers among the triple-jabbed increased at a very high rate (Table 1). In later period b), all age groups show a decrease (between 2.5 times to 5 times) in cases for the unvaccinated population compared to that from people of respective age groups with third doses. Whereas, in the earlier period a) the performances were mixed and not so consistent. For 30 to 79 years of age, though unvaccinated still performed better, but that did not even exceed 2.5 times.

Scotland's health authority, the Public Health Scotland (PHS) also publishes more detailed representations of weekly progression among vaccinated and unvaccinated categories. Table S2 shows the progression of cases between 11<sup>th</sup> December '21 to 7<sup>th</sup> January '22 (PHS<sup>9</sup>). The report suggests that infections with COVID-19 are more common among people who have had at least one dose than in the unvaccinated group (Table S2, PHS<sup>9</sup>). It is true for hospitalisation too (not shown here). Also, mortality is considerably more probable for people with 2 doses than for those who are unvaccinated (PHS<sup>9</sup>). As time progresses, how people with third doses will fare in Scotland compared to the unvaccinated group will be more evident, though can easily be speculated looking at data of later period from UHSA<sup>5</sup>. However, both the UK and Scotland

---

UHSA<sup>8</sup> :

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1036047/Vaccine\\_surveillance\\_report\\_-\\_week\\_47.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1036047/Vaccine_surveillance_report_-_week_47.pdf)

PHS<sup>9</sup>: [https://publichealthscotland.scot/media/11076/22-01-12-covid19-winter\\_publication\\_report.pdf](https://publichealthscotland.scot/media/11076/22-01-12-covid19-winter_publication_report.pdf)

**Table-1:** Unadjusted rates of COVID-19 infection in vaccinated and unvaccinated populations in UK. Cases reported by specimen date between, a) week 43, 2021 (25<sup>th</sup> October) and week 46, 2021 (15 November) [UHSA<sup>8</sup>, their Table 11] ; b) week 9, 2022 (w/e 6 March 2022) and week 12, 2022 (w/e 27 March 2022) [UHSA<sup>5</sup>, their Table 14].

| Age Groups | a) Week 43 to 46   |  | b) Week 9 to 12  |  |
|------------|--|--|--|--|
|            | Unadjusted rates among persons vaccinated with at least <b>2 doses</b> (per 100,000) | Unadjusted rates among persons <b>not vaccinated</b> (per 100,000) | Unadjusted rates among persons vaccinated with at least <b>3 doses</b> (per 100,000) | Unadjusted rates among persons <b>not vaccinated</b> (per 100,000) |
| 18 to 29   | 757.1  | 837.6  | 3,118.8  | 941.6  |
| 30 to 39   | 1,373.1  | 967.0  | 4,324.7  | 1,085.6  |
| 40 to 49   | 2,022.9  | 933.8  | 3,957.8  | 955.3  |
| 50 to 59   | 1,422.5  | 697.0  | 3,303.4  | 779.8  |
| 60 to 69   | 1,015.6  | 504.1  | 2,814.9  | 572.8  |
| 70 to 79   | 538.2  | 422.7  | 2,161.5  | 532.1  |
| 80 or over | 320.7  | 410.0  | 2,023.7  | 775.6  |

**N.B.** The rates are calculated per 100,000 in people who have received either 2<sup>nd</sup> doses (a), or 3<sup>rd</sup> doses (b), of a COVID-19 vaccine or in people who have not received a COVID-19 vaccine. Calculations are updated every week as the number of unvaccinated people and individuals vaccinated with 2<sup>nd</sup> or 3<sup>rd</sup> doses in the population changes.

governments stopped publishing the same data on vaccinated vs. unvaccinated in a recent period; Scotland stopped in mid-Feb, while the UK from April 2022. Our previous discussion suggests it is very likely that the UK and more specifically highly vaccinated Scotland will show a major surge in cases and deaths among vaccinated people with the third dose, as time progresses. Scotland the topmost vaccinated country in the UK (also one of the topmost vaccinated, globally) showed a maximum surge in cases/deaths in recent periods, though most stringent measures (face covering and many other restrictions) continued longer unlike most of the UK.

Such observation may explain why there was an unprecedented rise in cases and deaths in all those nine highly vaccinated countries after the initiation of the third dose.

### 3.5. Frequent vaccination, 'Exhaustion of T cells' and impaired immunity:

Further explanations based on scientific perspectives can also be offered that might support unusual COVID-19 situations as discussed for those countries. A well-known effect of vaccines known as 'exhaustion of T cells' may provide an explanation [13, 14]. The destructive effects of tampering with T cells are acknowledged in many popular articles [13, 14]. The findings presented here confirm concerns as expressed by the European Union's top drug regulator. Dr Marco Cavaleri, the European Medicines Agency's head of vaccines strategy, raised that issue at

a news briefing (Newspaper<sup>10</sup>). Dr Cavaleri mentioned a concern that seeing antigens, (those generated by vaccines), over and over again can lead to T cell anergy or 'exhaustion'. Prof Sarah Fortune, a professor at the Harvard TH Chan School of Public Health Department of Immunology and Infectious Diseases seconded such a possibility (Newspaper<sup>10</sup>). T cells play a key role in fighting COVID-19 once it has entered the body [14]. Multiple doses of vaccine can exhaust the T cells and subsequently weaken immune response.

Published research is also available that further discussed the suppression of immune response [9]. Their research suggested that in human cells, anti-COVID-19 vaccines actively suppress type I interferon (IFN) signaling. In general, type I and II interferons are accountable for activating and regulating the immune response [15]. Suppression of type I IFN responses results in impaired innate immunity. Subversion of innate immunity, primarily via suppression of interferon type I and its associated signaling cascade can have various wider consequences. It might cause reactivation of latent viral infections and can reduce the capability to fight effectively future infections [9].

Moreover, the antibodies fade over time, and once antibody levels are no longer high, the virus is able to enter cells more readily, and it is at this point that a type 1 interferon response is essential for clearing the virus. If the type 1 interferon response remains suppressed due to the vaccine after the antibody levels have fallen, it could set up a situation where susceptibility to infection is worse than it was prior to any vaccine. Those may provide explanations for why there is an unusual surge of COVID-19 cases as well as deaths in recent periods among vaccinated groups compared to the unvaccinated ones [Table 1, Table S1 and S2].

#### **4. Conclusions**

Considering the unprecedented recent COVID-19 situations in the following groups- a) among some topmost vaccinated countries e.g., Singapore, South Korea, Australia, Hong Kong, Iceland, New Zealand, Denmark, Finland and Japan; b) country that leads the vaccine roll-out programme viz. Israel; and c) country that is fully vaccinated for the longest period viz. Gibraltar - an obvious question arises as to what purpose was being served to those countries. Knowing many adverse effects of vaccines, noting the effectiveness of vaccination wanes in only few months' time and considering the heavy economic burden of mass vaccination globally every few months, many burning questions erupt on mass vaccination strategy. If situations became worst and unprecedented in the recent period for the whole of the pandemic, what objectives have those leading countries have achieved in controlling COVID transmission. These are few critical questions discussed and addressed on current COVID-19 exit strategies based on global mass vaccination.

Furthermore, observations indicate an unusual surge of cases as well as deaths in later periods among fully vaccinated groups compared to the unvaccinated ones. Hence one apparent issue

---

Newspaper<sup>10</sup>: <https://www.dw.com/en/covid-do-multiple-boosters-exhaust-our-immune-response/a-60447735> dt 18.01.22 accessed on 15/04/22.

arises whether high vaccination among the general population is causing them to lose natural immunity or not. All observed facts are supported by a well-known scientific theory relating to vaccination known as 'Exhaustions of T Cell'. It indicates high vaccination may weaken innate immune response. Other research further discussed that anti-COVID-19 vaccines actively suppress type I interferon signaling which can result in impaired innate immunity. As type I interferons are heavily responsible for activating and regulating the immune response, such a process can cause the reactivation of latent viral infections and reduce the capability to fight effectively against future infections. Those may provide explanations for an unusual surge of COVID-19 cases and deaths in recent periods among vaccinated groups. It is now high time to check these observed data and take urgent policy actions worldwide. Other additional policy measures are also proposed that will have enormous socio-economic impacts and will help bring back normalcy sooner.

### **Additional Policy Recommendations:**

A few propositions are also mentioned here. People all over the world will appreciate such endeavour, regardless of who agrees or disagree with frequent vaccine doses and child vaccinations.

- a) Countries should investigate adverse reactions and if responsible, vaccine companies should be made liable to compensate for harms and deaths.
- b) Out of any announced global crisis and emergency, no one should be allowed to make profits. The huge profits so far made by vaccine companies and related businesses should be taxed under a specific COVID-19 tax scheme.

These two measures (a and b) not only have enormous socio-economic impacts but will also help bring us back to normalcy sooner.

### **Abbreviations**

**CDC:** Centers for Disease Control and Prevention

**COVID-19:** COronaVIrus Disease 2019

**SARS-CoV-2:** Severe Acute Respiratory Syndrome CoronaVirus 2

**IFN:** interferon

**CSSE:** Center for Systems Science and Engineering

**JHU:** Johns Hopkins University

**PHS:** Public Health Scotland

**UHSA:** UK Health Security Agency

**WHO:** World Health Organisation

## Declarations

This study did not receive any funding and there is no conflict of interest.

Ethics approval and consent to participate: NA

Consent for publication: Yes

Availability of data and material: All data used are open source.

Competing interests: No competing interest

Funding: No funding received

Acknowledgements: Author acknowledges open data source for providing all COVID related data.


## References

1. Website: Ourworldindata, <https://ourworldindata.org/coronavirus-data-explorer> accessed 16/04/2022.
- 1a. Li, Q.; Guan, X.; Wu, P.; Wang, X.; Zhou, L.; Tong, Y.; Ren, R.; Leung, K.; Lau, E.; Wong, J.; et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N. Engl. J. Med.* **2020**, *382*, 1199–1207.
2. Gorbalenya AE, Baker SC, Baric RS et al. (2020) The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Natural Microbiology*;5:536–544. <https://doi.org/10.1038/s41564-020-0695-z>
3. Chen Yu and Lanjuan Li, (2020), SARS-CoV-2: virus dynamics and host response, *The Lancet*, 20, 5, P515-516, MAY 01, 2020, DOI:[https://doi.org/10.1016/S1473-3099\(20\)30235-8](https://doi.org/10.1016/S1473-3099(20)30235-8).
- 3a. Perez-Then, E. et al. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. *Nat. Med.* **28**, 481–485 (2022).
- 3b. Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*. **372**, eabg3055 (2021).
- 3c. Liu, Y. & Rocklöv, J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. *J. Travel Med.* **28**, taab124 (2021).
- 3d. Liu, Y., Gayle, A. A., Wilder-Smith, A. & Rocklöv, J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. *J. Travel Med.* **27**, taaa021 (2020).
4. Heinz, F.X., Stiasny, K. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. *npj Vaccines* **6**, 104 (2021). <https://doi.org/10.1038/s41541-021-00369-6>
5. Doshi P, *BMJ* 2020, Will covid-19 vaccines save lives? Current trials aren't designed to tell us; 371 doi: <https://doi.org/10.1136/bmj.m4037>, *BMJ* 2020;371:m4037 <https://www.bmj.com/content/371/bmj.m4037>.

6. Godlee, F, 2020, 'Covid-19: We need new thinking and new leadership' BMJ, <https://www.bmj.com/content/371/bmj.m4358>
7. Roy, I 2021: Exit Strategy from COVID-19: Vaccination and Alternate Solution, Bioengineering and Biomedical Signal and Image Processing. BIOMESIP 2021, Lecture Notes in Computer Science (LNCS), Springer Nature, vol 12940, pp. 1–16, DOI:10.1007/978-3-030-88163-4\_38.
- 7a. Roy, I. et al (2023). Seasonality, Mass Vaccination and critical policy evaluation on Global Exit Strategy of COVID-19 crisis. *Physics and Chemistry of the Earth, Part A/B/C Elsevier*, DOI: [10.1016/j.pce.2023.103388](https://doi.org/10.1016/j.pce.2023.103388)
8. Sanders, R.W. 2021, 'Pandemic moves and countermoves: vaccines and viral variants', The Lancet, DOI: [https://doi.org/10.1016/S0140-6736\(21\)00730-3](https://doi.org/10.1016/S0140-6736(21)00730-3).
- 8a. Roy, I (2022), Combating COVID-19 crisis and exploring heat-based simple solutions, *Physics and Chemistry of the Earth, Parts A/B/C* 129, 103333, Elsevier, ISSN 1474-7065, <https://doi.org/10.1016/j.pce.2022.103333>.
9. Seneff S, Nigh G, Kyriakopoulos AM et al. 2022, Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs, *Food and Chemical Toxicology*, Volume 164, 113008, ISSN 0278-6915, <https://doi.org/10.1016/j.fct.2022.113008>.
10. Seneff, S., & Nigh, G. (2021). Worse Than the Disease? Reviewing Some Possible Unintended Consequences of the mRNA Vaccines Against COVID-19. *International Journal of Vaccine Theory, Practice, and Research*, 2(1), 38–79.
11. Shrotri, M, A.M. Navaratnam, V. Nguyen, T. Byrne, C. Geismar, E. Fragaszy, S. Beale, W.L.E. Fong, P. Patel, J. Kovar, et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1, *Lancet*, 398 (10298) (2021), pp. 385-387
- 11a. Mansanguan, S.; Charunwatthana, P.; Piyaphanee, W.; Dechkhajorn, W.; Poolcharoen, A.; Mansanguan, C. Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents. *Trop. Med. Infect. Dis.* **2022**, *7*, 196. <https://doi.org/10.3390/tropicalmed7080196>
12. Burki, T. K. (2022) Fourth dose of COVID-19 vaccines in Israel, *The Lancet*, DOI: [https://doi.org/10.1016/S2213-2600\(22\)00010-8](https://doi.org/10.1016/S2213-2600(22)00010-8)
13. Blank, C.U., Haining, W.N., Held, W. et al. Defining 'T cell exhaustion'. *Nat Rev Immunol* **19**, 665–674 (2019). <https://doi.org/10.1038/s41577-019-0221-9>
14. Rha, MS., Shin, EC. Activation or exhaustion of CD8<sup>+</sup> T cells in patients with COVID-19. *Cell Mol Immunol* **18**, 2325–2333 (2021). <https://doi.org/10.1038/s41423-021-00750-4>

15. Parkin J, Cohen B (June 2001). "An overview of the immune system". *Lancet*. **357** (9270): 1777–89. doi:10.1016/S0140-6736(00)04904-7. PMID 11403834. S2CID [165986](#)


Supplementary Section




**Fig. S1.** COVID-19 vaccine doses administered based on manufacturer for a) European Union and b) US. All doses, including boosters, are counted individually. In both cases, majority are shown administered Pfizer-BioNTech vaccine followed by Moderna.

[Source: Our World in Data (1)]


a)




b)




c)



d)




**Fig. S2.** Daily new confirmed COVID-19 cases and deaths per million people, 7-day rolling average, till 21<sup>st</sup> March 2022 for a) United States, b) Europe, c) UK and d) India  
[ Source: Our World in Data (1)]




**Fig. S3.** COVID-19 vaccine doses, further breakdown, in terms of initial doses and boosters per 100 people upto March 21, 2022 for few countries from Fig 1B. The total number of doses administered, broken down by whether they are part of the initial protocol or booster doses, divided by the total population of the country.

[ Source: Our World in Data (1)].


a)



b)



**Fig. S4.** Daily share of the population receiving a COVID-19 vaccine dose (7-day rolling average). All doses, including boosters, are counted individually. a) Hong Kong and Japan showed a sudden rise in vaccine dose in later period. b) Most countries decreased vaccine doses in later time. [Source: Our World in Data (1)]



**Fig. S5.** The country Gibraltar is highly ranked in terms of cumulative vaccine doses as well as cases. a) COVID-19 vaccine doses (cumulative) administered per 100 people. All doses, including boosters, are counted individually. b) Cumulative confirmed COVID-19 cases per million people. [ Source: Our World in Data (1)].

**Table S1.** COVID-19 deaths ( $\geq 50$  years age groups) (I) within 28 days, (II) within 60 days of positive specimen or with COVID-19 reported on Death certificate, by vaccination status between a) week 43- 46, 2021 [UHSA<sup>8</sup>, their Table 10 a, b]; b) week 9-12, 2022 [UHSA<sup>5</sup>, their Table 13 a, b].

| Week /Age groups (10 years band) | Total |      | Unlinked |    | Not Vaccinated |     | Received one dose, (1-20 days before specimen date) |    | Received one dose, $\geq 21$ days before specimen date |    | Second dose $\geq 14$ days before specimen date |      | Third dose $\geq 14$ days before specimen date |      |
|----------------------------------|-------|------|----------|----|----------------|-----|---|----|--|----|---|------|--|------|
|                                  | I     | II   | I        | II | I              | II  | I   | II | I  | II | I   | II   | I  | II   |
| <b>a)Week (43-46)</b>            |       |      |          |    |                |     |   |    |  |    |   |      |  |      |
| 50-59                            | 250   | 312  | 5        | 6  | 108            | 134 | 0   | 0  | 11   | 14 | 126   | 158  | Na   |      |
| 60-69                            | 555   | 658  | 3        | 5  | 154            | 181 | 0   | 0  | 18   | 20 | 380   | 452  |  |      |
| 70-79                            | 1025  | 1195 | 6        | 7  | 163            | 175 | 1   | 1  | 9  | 16 | 846   | 996  |  |      |
| $\geq 80$                        | 1726  | 2054 | 7        | 7  | 187            | 207 | 5   | 6  | 35   | 47 | 1492  | 1787 |  |      |
| Total                            | 3556  | 4219 |          |    | 612            | 697 |   |    |  |    | 2844  | 3393 |  |      |
| (% of deaths)                    |       |      |          |    | (17.2, 16.5)   |     |   |    |  |    | (79.9, 80.4)                                    |      |  |      |
| <b>b)Week (9-12)</b>             |       |      |          |    |                |     |   |    |  |    |   |      |  |      |
| 50-59                            | 72    | 155  | 0        | 0  | 16             | 24  | 0   | 0  | 5  | 8  | 17  | 45   | 34   | 78   |
| 60-69                            | 163   | 350  | 1        | 1  | 31             | 48  | 0   | 0  | 11   | 16 | 39  | 77   | 81   | 208  |
| 70-79                            | 435   | 825  | 3        | 3  | 48             | 72  | 0   | 0  | 6  | 19 | 70  | 120  | 308  | 611  |
| $\geq 80$                        | 1420  | 2614 | 5        | 5  | 104            | 145 | 1   | 2  | 23   | 36 | 175   | 320  | 1112   | 2106 |
| Total                            | 2090  | 3944 |          |    | 199            | 289 |   |    |  |    |   |      | 1535   | 3003 |
| (% of deaths)                    |       |      |          |    | (9.5, 7.3)     |     |   |    |  |    |   |      | (73.4, 76.1)                                   |      |

**Table-S2:** Age standardised Case rate per 100,000 people by vaccination status and week in Scotland between 11 December 2021 to 7<sup>th</sup> January 2022. Unvaccinated are performing the best in all weeks compared to any vaccinated groups. Double vaccinated are performing the worst in every week. [Source: PHS<sup>9</sup>, their Table 11]

| Week                              | Unvaccinated               |  | 1 Dose                     |  |
|-----------------------------------|----------------------------|--|----------------------------|--|
|                                   | No. tested positive by PCR | Age Standardised case rate per 100,000 with 95% confidence intervals | No. tested positive by PCR | Age Standardised case rate per 100,000 with 95% confidence intervals |
| 11 December - 17 December 2021    | 6,545                      | <b>482.87</b> (464.41 - 501.34)                                      | 2,952                      | <b>574.16</b> (538.46 - 609.85)                                      |
| 18 December - 24 December 2021    | 9,070                      | <b>721.39</b> (698.44 - 744.34)                                      | 4,639                      | <b>958.62</b> (911.03 - 1,006.20)                                    |
| 25 December - 31 December 2021    | 14,465                     | <b>1,242.10</b> (1,209.27 - 1,274.94)                                | 7,657                      | <b>1,693.71</b> (1,631.31 - 1,756.11)                                |
| 01 January 2022 – 07 January 2022 | 12,485                     | <b>1,092.80</b> (1,063.90 - 1,121.71)                                | 6,702                      | <b>1,527.57</b> (1,462.52 - 1,592.63)                                |
| Week                              | 2 Doses                    |  | Booster or 3rd Dose        |  |
|                                   | No. tested positive by PCR | Age Standardised case rate per 100,000 with 95% confidence intervals | No. tested positive by PCR | Age Standardised case rate per 100,000 with 95% confidence intervals |
| 11 December - 17 December 2021    | 20,788                     | <b>826.49</b> (809.83 - 843.16)                                      | 3,926                      | <b>458.39</b> (400.49 - 516.29)                                      |
| 18 December - 24 December 2021    | 35,123                     | <b>1,527.87</b> (1,501.86 - 1,553.88)                                | 10,193                     | <b>902.02</b> (841.06 - 962.98)                                      |
| 25 December - 31 December 2021    | 54,860                     | <b>2,897.58</b> (2,859.92 - 2,935.23)                                | 30,327                     | <b>1,755.69</b> (1,701.98 - 1,809.40)                                |
| 01 January 2022 – 07 January 2022 | 35,119                     | <b>2,499.52</b> (2,462.50 - 2,536.53)                                | 33,415                     | <b>1,466.76</b> (1,418.18 - 1,515.33)                                |